Tidal Investments LLC Has $1.75 Million Stake in Bruker Corporation $BRKR

Key Points

• Tidal Investments increased its Bruker stake by 180.4% in the second quarter, ending with 29,092 shares worth approximately $1.75 million. Institutional investors collectively own 79.52% of BRKR.
• Analyst sentiment is mixed, with a consensus rating of “Hold” and an average price target of $57, below the reported share price of $63.05. JPMorgan raised its target to $65 and maintained an “overweight” rating.
• Bruker beat quarterly EPS estimates, reporting $0.49 versus the expected $0.38, while revenue rose 5.2% year over year to $838.5 million. The company also declared a quarterly dividend of $0.05 per share, yielding about 0.3% annually.

Tidal Investments LLC lifted its position in Bruker Corporation (NASDAQ:BRKR - Free Report) by 180.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 29,092 shares of the medical research company's stock after buying an additional 18,715 shares during the quarter. Tidal Investments LLC's holdings in Bruker were worth $1,751,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in BRKR. Pallas Capital Advisors LLC acquired a new stake in Bruker in the second quarter valued at approximately $570,746,000. Sculptor Capital LP increased its stake in shares of Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock worth $118,112,000 after purchasing an additional 270,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in shares of Bruker during the 2nd quarter valued at $169,899,000. Dimensional Fund Advisors LP raised its holdings in shares of Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company's stock valued at $84,556,000 after purchasing an additional 448,440 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock valued at $108,796,000 after purchasing an additional 1,756,460 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on BRKR. Wolfe Research assumed coverage on shares of Bruker in a research report on Monday, June 1st. They set a "peer perform" rating on the stock. JPMorgan Chase & Co. boosted their price target on Bruker from $55.00 to $65.00 and gave the stock an "overweight" rating in a research report on Monday, June 8th. TD Cowen reiterated a "hold" rating on shares of Bruker in a research note on Wednesday, July 15th. Stifel Nicolaus set a $50.00 price objective on Bruker in a report on Wednesday, August 5th. Finally, UBS Group initiated coverage on Bruker in a report on Wednesday, September 9th. They set a "neutral" rating and a $65.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Bruker has a consensus rating of "Hold" and an average price target of $57.00.

Bruker Stock Performance

NASDAQ:BRKR opened at $63.05 on Friday. Bruker Corporation has a 1 year low of $30.09 and a 1 year high of $65.30. The firm's fifty day simple moving average is $58.14 and its 200 day simple moving average is $49.82. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $9.61 billion, a PE ratio of -90.07, a PEG ratio of 1.86 and a beta of 1.26.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker's payout ratio is presently -28.57%.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the business's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the transaction, the vice president owned 134,806 shares of the company's stock, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 27.20% of the company's stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.